Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
Table 1
Demographic data of the study participants.
Sporadic PD
LRRK2-PD
Asymptomatic LRRK2 carriers
Control
17
10
11
19
Age
61.9 ± 7.6
70.4 ± 11.7a
63.4 ± 11.3
57.7 ± 8.3
Sex (male/female)
13/4
6/4
5/6
10/9
CSF free cells (106/L)
1.5 ± 1.1
1.2 ± 1.1
2.0 ± 1.1
2.2 ± 1.4
CSF total protein (g/L)
0.45 ± 0.24
0.50 ± 0.24
0.46 ± 0.12
0.40 ± 0.10
Age at disease onset
54.7 ± 10.5
58.5 ± 10.3
Duration of disease (y)
8.0 ± 5.9
11.9 ± 7.1
Hoehn and Yahr
2.5 ± 0.98
2.6 ± 0.96
Levodopa/carbidopa (mg/day)
403 ± 295
385 ± 111
Levodopa (equivalent daily dose, LEDD)
529 ± 321
515 ± 233
Results are given as the mean ± SD. PD = Parkinson’s disease. There were no significant differences between the groups for CSF free cells or total protein (nor between the two groups with PD for levodopa or LEDD). There was a significant difference in age between the control and LRRK2-PD groups, .
